Healthcare Resource Utilization and Cost Among Patients Treated for Early-Stage Triple-Negative Breast Cancer

Abstract

<b>Background:</b> This retrospective, observational study examined real-world healthcare resource utilization (HCRU) and costs in 308 patients diagnosed with early-stage (II-IIIB) triple-negative breast cancer between 1 March 2008 and 31 March 2016. <b>Methods:</b> HCRU and costs were evaluated for two time periods: from neoadjuvant treatment start date to surgery (Time 1) and after surgery to recurrence or death (Time 2). <b>Results:</b> The sample included 236 patients who received neoadjuvant treatment without subsequent adjuvant treatment (Neo) and 72 patients who received neoadjuvant treatment followed by adjuvant treatment (Neo + adj). Mean monthly HCRU events and mean monthly costs per patient were higher in Time 1 compared with Time 2 for both groups. <b>Conclusion:</b> These results demonstrate the economic burden of early-stage triple-negative breast cancer especially during neoadjuvant treatment phase.